Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 11/2018

01-11-2018 | Review

Denosumab in the treatment of glucocorticoid-induced osteoporosis

Author: Ilke Coskun Benlidayi

Published in: Rheumatology International | Issue 11/2018

Login to get access

Abstract

Glucocorticoid therapy is the number one cause of secondary osteoporosis particularly effecting young individuals. Possessing an increased risk for fractures, glucocorticoid-induced osteoporosis might interfere with patients’ well-being and quality of life. Therefore, proper treatment of bone loss and prevention from fractures are of great importance. There are a limited number of therapeutic and preventative options for glucocorticoid-induced osteoporosis. Denosumab, with its high anti-resorptive potential, has been studied several times among patients on glucocorticoid therapy. However, a comprehensive look analysing the current data is lacking. Thus, the objective of the current article is to evaluate the current evidence on the efficacy, as well as the safety profile of denosumab in glucocorticoid-induced osteoporosis. Pubmed/MEDLINE, Scopus and Web of Science databases were searched for the terms denosumab, glucocorticoid-induced osteoporosis, steroid-induced osteoporosis, glucocorticoids and osteoporosis. Relevant data regarding the efficacy and safety of denosumab among patients with glucocorticoid-induced osteoporosis was analysed. Denosumab contributes to increased bone mineral density and decreased bone-turnover marker levels among glucocorticoid users. It is an effective therapeutic option with a favourable safety profile in glucocorticoid-induced osteoporosis.
Literature
1.
Saag KG, Buttgereit F (2019) Systemic glucocorticoids in rheumatology. In: Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology, 7th edn. Elsevier, Philadelphia, pp 488–498
2.
Curtis J, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V et al (2006) Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55:420–426CrossRef
3.
Hsu E, Nanes M (2017) Advances in treatment of glucocorticoid-induced osteoporosis. Curr Opin Endocrinol Diabetes Obes 24:411–417CrossRef
4.
Coskun Benlidayi I, Basaran S, Evlice A, Erdem M, Demirkiran M (2015) Prevalence and risk factors of low bone mineral density in patients with multiple sclerosis. Acta Clin Belg 70:188–192CrossRef
5.
Pereira RM, Carvalho JF, Canalis E (2010) Glucocorticoid-induced osteoporosis in rheumatic diseases. Clinics (Sao Paulo) 65:1197–1205CrossRef
6.
Rossini M, Viapiana O, Vitiello M, Malavolta N, La Montagna G, Maddali Bongi S et al (2017) Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study. Reumatismo 69:30–39CrossRef
7.
Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD et al (2016) Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int 27:1709–1718CrossRef
8.
Kim D, Cho SK, Park B, Jang EJ, Bae SC, Sung YK (2018) Glucocorticoids are associated with an increased risk for vertebral fracture in patients with rheumatoid arthritis. J Rheumatol 45:612–620CrossRef
9.
Nazrun AS, Tzar MN, Mokhtar SA, Mohamed IN (2014) A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality. Ther Clin Risk Manag 10:937–948PubMedPubMedCentral
10.
González-Macías J, Del Pino-Montes J, Olmos JM, Nogués X, en nombre de la Comisión de Redacción de las Guías de Osteoporosis de la SEIOMM (2015) Clinical practice guidelines for posmenopausal, glucocorticoid-induced and male osteoporosis. Spanish Society for Research on Bone and Mineral Metabolism (3rd updated version 2014). Rev Clin Esp 215:515–526CrossRef
11.
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE et al (2017) 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 69:1521–1537CrossRef
12.
Briot K, Cortet B, Roux C, Fardet L, Abitbol V, Bacchetta J, Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO) et al (2014) 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Jt Bone Spine 81:493–501CrossRef
13.
Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Scientific Advisory Council of Osteoporosis Canada et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864–1873CrossRef
14.
Chitre M, Shechter D, Grauer A (2011) Denosumab for treatment of postmenopausal osteoporosis. Am J Health Syst Pharm 68:1409–1418CrossRef
15.
Gu HF, Gu LJ, Wu Y, Zhao XH, Zhang Q, Xu ZR et al (2015) Efficacy and safety of denosumab in postmenopausal women with osteoporosis: a meta-analysis. Medicine (Baltimore) 94:e1674CrossRef
16.
17.
Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417CrossRef
18.
19.
Jacobs JWG, Bijlsma JWJ (2017) Glucocorticoid therapy. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O’dell JR (eds) Kelley and Firestein’s textbook of rheumatology, 10th edn. Elsevier, Philedelphia, pp 932–957CrossRef
20.
Lau AN, Sambrook PN, Adachi JD (2015) Glucocorticoid-induced osteoporosis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology, 6th edn. Elsevier, Philadelphia, pp 1674–1678
21.
Rossini M, Gatti D, Adami S (2013) Involvement of WNT/β-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 93:121–132CrossRef
22.
Deal CL, Abelson AG (2019) Management of osteoporosis. In: Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology, 7th edn. Elsevier, Philadelphia, pp 1671–1682
23.
Kim K, Kim JH, Kim I, Lee J, Seong S, Park YW et al (2015) MicroRNA-26a regulates RANKL-induced osteoclast formation. Mol Cells 38:75–80PubMed
24.
Akbar MA, Nardo D, Chen MJ, Elshikha AS, Ahamed R, Elsayed EM et al (2017) Alpha-1 antitrypsin inhibits RANKL-induced osteoclast formation and functions. Mol Med 21:23
25.
Scott LJ (2014) Denosumab: a review of its use in postmenopausal women with osteoporosis. Drugs Aging 31:555–576CrossRef
26.
Mok CC, Ho LY, Ma KM (2015) Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone 75:222–228CrossRef
27.
Matsuno H (2016) Assessment of distal radius bone mineral density in osteoporosis patients receiving denosumab, including those with rheumatoid arthritis and those receiving oral glucocorticoids. Drugs R D 16:347–353CrossRef
28.
Iseri K, Iyoda M, Watanabe M, Matsumoto K, Sanada D, Inoue T et al (2018) The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: a randomized, controlled trial. PLoS One 13:e0193846CrossRef
29.
Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R et al (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 6:445–454CrossRef
30.
Petranova T, Sheytanov I, Monov S, Nestorova R, Rashkov R (2014) Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment. Biotechnol Biotechnol Equip 28:1127–1137CrossRef
31.
Sawamura M, Komatsuda A, Togashi M, Wakui H, Takahashi N (2017) Effects of denosumab on bone metabolic markers and bone mineral density in patients treated with glucocorticoids. Intern Med 56:631–636CrossRef
32.
Ishiguro S, Ito K, Nakagawa S, Hataji O, Sudo A (2017) The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease. Arch Osteoporos 12:44CrossRef
33.
Suzuki T, Nakamura Y, Kato H (2018) Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis. Mod Rheumatol 22:1–5
34.
Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, Denosumab RA Study Group et al (2010) Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 69:872–875CrossRef
35.
Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513–523CrossRef
36.
Deeks ED (2018) Denosumab: a review in postmenopausal osteoporosis. Drugs Aging 35:163–173CrossRef
37.
Beaudoin C, Jean S, Bessette L, Ste-Marie LG, Moore L, Brown JP (2016) Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Osteoporos Int 27:2835–2844CrossRef
38.
Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S et al (2013) Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol 121:1291–1299CrossRef
39.
Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A et al (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48–54CrossRef
40.
Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153–161CrossRef
41.
Fontalis A, Kenanidis E, Prousali E, Potoupnis M, Tsiridis E (2018) Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis. Expert Opin Drug Saf 17:413–428CrossRef
42.
Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972–980CrossRef
43.
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al FREEDOMTrial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRef
44.
Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471–1479CrossRef
45.
Bussiere JL, Pyrah I, Boyce R, Branstetter D, Loomis M, Andrews-Cleavenger D et al (2013) Reproductive toxicity of denosumab in cynomolgus monkeys. Reprod Toxicol 42:27–40CrossRef
46.
Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwiński E et al (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694–701CrossRef
47.
Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM et al (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int 26:2773–2783CrossRef
48.
Miller PD (2011) A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis 3:271–282CrossRef
49.
Bonani M, Frey D, Brockmann J, Fehr T, Mueller TF, Saleh L et al (2016) Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial. Am J Transplant 16:1882–1891CrossRef
50.
51.
Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, National Osteoporosis Guideline Group (NOGG) et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43CrossRef
52.
de Boissieu P, Kanagaratnam L, Mahmoudi R, Morel A, Dramé M, Trenque T (2017) Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review. Eur J Clin Pharmacol 73:517–523CrossRef
53.
Boquete-Castro A, Gómez-Moreno G, Calvo-Guirado JL, Aguilar-Salvatierra A, Delgado-Ruiz RA (2016) Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clin Oral Implants Res 27:367–375CrossRef
54.
Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA et al (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101:3163–3170CrossRef
Metadata
Title
Denosumab in the treatment of glucocorticoid-induced osteoporosis
Author
Ilke Coskun Benlidayi
Publication date
01-11-2018
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 11/2018
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-018-4106-1

Other articles of this Issue 11/2018

Rheumatology International 11/2018 Go to the issue

Correction

Correction to: Sleep and physical activity: a cross-sectional objective profile of people with rheumatoid arthritis

Public Health

Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis

Physical Medicine and Rehabilitation

Associations between fatigue and physical capacity in people moderately affected by rheumatoid arthritis

Systematic Review

Efficacy of commonly prescribed analgesics in the management of osteoarthritis: a systematic review and meta-analysis

Validation Studies

Validation and cultural adaptation of the qualisex questionnaire in patients with axial spondyloarthritis in Argentina

Clinical Trials

Long-term etanercept survival in patients with psoriatic arthritis: a multicenter retrospective analysis in daily clinical practice in Spain
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits